Metformin in Diabetes Management and Immune Modulation: A Comprehensive Review.

IF 1.5 4区医学 Q4 ALLERGY

Iranian journal of allergy, asthma, and immunology Pub Date : 2026-01-01 DOI:10.18502/ijaai.v25i1.20431

Mehrangiz Ghafari, Javad Poursamimi, Foroogh Asli

引用次数: 0

Abstract

Metformin is a primary treatment for type 2 diabetes (T2D), well-known for its ability to lower blood glucose levels through both AMP-activated protein kinase (AMPK)-dependent and -independent pathways. Recent evidence suggests that metformin also possesses immunomodulatory properties, indicating its potential as a therapeutic agent that extends beyond metabolic regulation. This review summarizes the current understanding of metformin's dual roles in managing diabetes and modulating the immune system. It also explores the underlying mechanisms, clinical implications, and potential directions for future research.

查看原文本刊更多论文

二甲双胍在糖尿病管理和免疫调节中的应用综述。

二甲双胍是2型糖尿病（T2D）的主要治疗药物，因其通过amp激活的蛋白激酶（AMPK）依赖和非依赖途径降低血糖水平而闻名。最近的证据表明，二甲双胍还具有免疫调节特性，表明其作为一种治疗药物的潜力超出了代谢调节。这篇综述总结了目前对二甲双胍在治疗糖尿病和调节免疫系统中的双重作用的理解。并探讨了其潜在机制、临床意义和未来研究的潜在方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian journal of allergy, asthma, and immunology 医学-过敏

CiteScore

2.60

自引率

6.70%

发文量

审稿时长

>12 weeks

期刊介绍： The Iranian Journal of Allergy, Asthma and Immunology (IJAAI), an international peer-reviewed scientific and research journal, seeks to publish original papers, selected review articles, case-based reviews, and other articles of special interest related to the fields of asthma, allergy and immunology. The journal is an official publication of the Iranian Society of Asthma and Allergy (ISAA), which is supported by the Immunology, Asthma and Allergy Research Institute (IAARI) and published by Tehran University of Medical Sciences (TUMS). The journal seeks to provide its readers with the highest quality materials published through a process of careful peer reviews and editorial comments. All papers are published in English.